Table 1:
Demographic and Clinical Characteristics Comparing Tumor ERα Positivity
| Characteristic | HNSCC (n=318) | OPC (n=180) | ||||
|---|---|---|---|---|---|---|
| ERα negative (<1%) n=203, 63.8% | ERα positive (>=1%) n=115, 36.2% | p | ERα negative (<1%) n=77, 42.8% | ERα positive (>=1%) n=103, 57.2% |
p | |
| Study site | ||||||
| JHU/GBMC | 139 (68.5) | 77 (67.0) | 0.59 | 57 (74.0) | 69 (67.0) | 0.40 |
| UCSF | 40 (19.7) | 20 (17.4) | 8 (10.4) | 18 (17.5) | ||
| MSSM | 24 (11.8) | 19 (15.7) | 12 (15.6) | 16 (15.5) | ||
| Race | ||||||
| Non-Hispanic white | 164 (80.8) | 96 (83.5) | 0.74 | 67 (87.0) | 87 (84.5) | 0.77 |
| Non-Hispanic black | 21 (10.3) | 13 (11.3) | 6 (7.8) | 10 (9.7) | ||
| Hispanic | 8 (3.9) | 4 (3.5) | 1 (1.3) | 4 (3.9) | ||
| Asian/Pacific Islander | 7 (3.5) | 1 (0.9) | 1 (1.3) | 1 (1.0) | ||
| Other/multiracial | 3 (1.5) | 1 (0.9) | 2 (2.6) | 1 (1.0) | ||
| Age | ||||||
| <= 60 years | 110 (54.2) | 60 (52.2) | 0.73 | 50 (65.0) | 59 (57.3) | 0.30 |
| >60 years | 93 (45.8) | 55 (47.8) | 27 (35.1) | 44 (42.7) | ||
| Sex | ||||||
| Female | 52 (25.6) | 17 (14.8) | 0.024 | 15 (19.5) | 13 (12.6) | 0.21 |
| Male | 151 (74.4) | 98 (85.2) | 62 (80.5) | 90 (87.4) | ||
| Sexual orientation | ||||||
| Heterosexual | 168 (82.8) | 95 (82.6) | 0.40 | 68 (88.3) | 87 (84.5) | 0.48 |
| Homosexual/Bisexual/Other | 8 (3.9) | 8 (7.0) | 2 (2.6) | 7 (6.8) | ||
| BMI | ||||||
| Normal/Underweight (<25) | 70 (40.5) | 27 (26.0) | 0.01 | 27 (39.1) | 24 (25.5) | 0.07 |
| Overweight/Obese (>=25) | 103 (59.5) | 77 (74.0) | 42 (60.9) | 70 (74.5) | ||
| Marital Status | ||||||
| Married/living with partner | 63 (35.4) | 25 (24.0) | 0.05 | 55 (78.6) | 72 (75.8) | 0.68 |
| Widowed/Divorced/Other | 115 (64.6) | 79 (76.0) | 15 (21.4) | 23 (24.2) | ||
| Highest Degree | ||||||
| Less than high school | 12 (6.7) | 6 (5.8) | 0.99 | 4 (5.7) | 5 (5.3) | 0.94 |
| HS or GED | 39 (21.9) | 21 (20.2) | 11 (15.7) | 20 (21.1) | ||
| Some college | 32 (18.0) | 18 (17.3) | 12 (17.1) | 15 (15.8) | ||
| College grad | 55 (30.9) | 35 (33.7) | 26 (37.1) | 32 (33.7) | ||
| Graduate degree | 40 (22.5) | 24 (23.1) | 17 (24.3) | 23 (24.2) | ||
| >5 years in named “risky job” | ||||||
| No | 167 (82.3) | 97 (84.4) | 0.64 | 64 (83.1) | 85 (82.5) | 0.92 |
| Yes | 36 (17.7) | 18 (15.7) | 13 (16.9) | 18 (17.5) | ||
| Drinking status | ||||||
| Never | 2 (1.4) | 5 (5.9) | 0.10 | 0 (0) | 4 (5) | 0.22 |
| Current | 63 (44.7) | 42 (50.6) | 34 (56.7) | 40 (50.6) | ||
| Former | 76 (53.9) | 37 (43.5) | 26 (43.4) | 35 (44.3) | ||
| Ever smoke | ||||||
| No | 59 (33.7) | 30 (28.9) | 0.40 | 24 (34.3) | 29 (30.9) | 0.64 |
| Yes | 116 (66.3) | 74 (71.2) | 46 (65.7) | 65 (69.2) | ||
| Ever use drugs | ||||||
| No | 66 (37.5) | 27 (26.0) | 0.05 | 18 (25.7) | 23 (24.5) | 0.85 |
| Yes | 110 (62.5) | 77 (74.0) | 52 (74.3) | 71 (75.5) | ||
| Ever used marijuana | ||||||
| No | 67 (38.1) | 29 (27.6) | 0.074 | 19 (27.1) | 25 (26.3) | 0.90 |
| Yes | 109 (61.9) | 76 (72.4) | 51 (72.9) | 70 (73.7) | ||
| Comorbidities | ||||||
| Asthma | ||||||
| No | 157 (89.2) | 91 (85.6) | 0.73 | 66 (95.7) | 82 (87.2) | 0.16 |
| Yes | 16 (9.1) | 12 (11.5) | 3 (4.4) | 11 (11.7) | ||
| Diabetes | ||||||
| No | 149 (84.7) | 94 (90.4) | 0.17 | 67 (97.1) | 86 (91.5) | 0.19 |
| Yes | 27 (15.3) | 10 (9.6) | 2 (2.9) | 8 (8.5) | ||
| Coronary heart disease | ||||||
| No | 150 (85.2) | 100 (96.2) | 0.002 | 62 (89.9) | 90 (95.7) | 0.098 |
| Yes | 25 (14.2) | 3 (2.9) | 7 (10.1) | 3 (3.2) | ||
| Stroke | ||||||
| No | 167 (94.4) | 101 (97.1) | 0.21 | 68 (97.1) | 92 (97.9) | 0.76 |
| Yes | 8 (4.5) | 1 (1.0) | 2 (2.9) | 1 (1.1) | ||
| Anemia | ||||||
| No | 146 (82.5) | 102 (98.1) | <0.001 | 61 (87.1) | 92 (97.9) | 0.01 |
| Yes | 29 (16.4) | 2 (1.9) | 9 (12.9) | 2 (2.1) | ||
| HIV | ||||||
| No | 171 (97.1) | 102 (99.0) | 0.42 | 67 (97.1) | 92 (98.9) | 0.58 |
| Yes | 5 (2.8) | 1 (1.0) | 2 (2.9) | 1 (1.1) | ||
| STI | ||||||
| No | 145 (82.4) | 75 (72.1) | 0.04 | 56 (81.2) | 67 (71.3) | 0.28 |
| Yes | 31 (17.6) | 28 (26.9) | 13 (18.8) | 26 (27.7) | ||
| Autoimmune disease | ||||||
| no | 161 (91.1) | 96 (92.3) | 0.94 | 67 (95.7) | 88 (93.6) | 0.87 |
| yes | 12 (6.8) | 6 (5.8) | 2 (2.9) | 4 (4.3) | ||
| Genital warts | ||||||
| No | 158 (90.0) | 90 (87.4) | 0.46 | 57 (81.4) | 80 (86.0) | 0.43 |
| Yes | 18 (10.2) | 12 (11.7) | 13 (18.6) | 12 (12.9) | ||
| History of any cancer | ||||||
| No | 138 (78.0) | 78 (74.3) | 0.48 | 56 (80) | 71 (74.7) | 0.43 |
| Yes | 39 (22.0) | 27 (25.7) | 14 (20) | 24 (25.3) | ||
| Oncologic Characteristics | ||||||
| Tumor site | ||||||
| Oropharynx | 77 (37.9) | 103 (89.6) | <0.001 | |||
| Oral Cavity | 92 (45.3) | 4 (3.5) | ||||
| Nasopharynx | 1 (0.5) | 1 (0.9) | ||||
| Larynx | 27 (13.3) | 1 (0.9) | ||||
| Other site | 6 (3.0) | 6 (5.2) | ||||
| Tumor site | ||||||
| Non-Oropharynx | 126 (62.1) | 12 (10.4) | <0.001 | |||
| Oropharynx | 77 (37.9) | 103 (89.6) | ||||
| HPV-related | ||||||
| Negative | 129 (64.5) | 7 (6.2) | <0.001 | 14 (18.7) | 1 (1.0) | <0.001 |
| Positive | 71 (35.5) | 106 (93.8) | 61 (81.3) | 100 (99.0) | ||
| p16 status | ||||||
| Negative | 123 (61.5) | 6 (5.3) | 15 (20) | 1 (1.0) | <0.001 | |
| Positive | 77 (38.5) | 107 (94.7) | <0.001 | 60 (80.0) | 100 (99.0) | |
| Treatment Modality | ||||||
| Surgery Only | 64 (31.5) | 19 (16.5) | 0.003 | 15 (19.5) | 17 (16.5) | 0.61 |
| Radiation Only | 7 (3.4) | 4 (3.4) | >.99 | 3 (3.9) | 4 (3.9) | 1 |
| Chemotherapy &radiation | 33 (16.3) | 23 (20) | 0.4 | 26 (33.8) | 23 (22.3) | 0.09 |
| Surgery & Chemoradiation | 39 (19.2) | 27 (23.4) | 0.37 | 14 (18.2) | 22 (21.4) | 0.71 |
| Serology Data (% positive) | ||||||
| HPV16 L1 | 62 (50) | 62 (50) | <0.001 | 47 (64.4) | 58 (62.4) | 0.79 |
| HPV16 E6 | 56 (28.9) | 88 (84.6) | <0.001 | 55 (75.3) | 82 (88.2) | 0.031 |
| HPV16 E7 | 46 (23.7) | 70 (67.3) | <0.001 | 41 (56.2) | 66 (71.0) | 0.048 |
| HPV16 E6 or E7 positive | 61 (31.4) | 90 (86.5) | <0.001 | 56 (76.7) | 84 (90.3) | 0.017 |
Abbreviations: HNSCC, Head & Neck Squamous Cell Carcinoma; OPC: Oropharynx cancer; JHU, Johns Hopkins University; UCSF, University of California; MSHS, Mount Sinai Health System; GED, General Educational Development; HIV human immunodeficiency virus; ISH, in-situ hybridization
Bolding indicates statistical significance.